Literature DB >> 10358163

MHC class II antigen processing in B cells: accelerated intracellular targeting of antigens.

P C Cheng1, C R Steele, L Gu, W Song, S K Pierce.   

Abstract

Processing and presentation by Ag-specific B cells is initiated by Ag binding to the B cell Ag receptor (BCR). Cross-linking of the BCR by Ag results in a rapid targeting of the BCR and bound Ag to the MHC class II peptide loading compartment (IIPLC). This accelerated delivery of Ag may be essential in vivo during periods of rapid Ag-driven B cell expansion and T cell-dependent selection. Here, we use both immunoelectron microscopy and a nondisruptive protein chemical polymerization method to define the intracellular pathway of the targeting of Ags by the BCR. We show that following cross-linking, the BCR is rapidly transported through transferrin receptor-containing early endosomes to a LAMP-1+, beta-hexosaminadase+, multivesicular compartment that is an active site of peptide-class II complex assembly, containing both class II-invariant chain complexes in the process of invariant chain proteolytic removal as well as mature peptide-class II complexes. The BCR enters the class II-containing compartment as an intact mIg/Igalpha/Igbeta complex bound to Ag. The pathway by which the BCR targets Ag to the IIPLC appears not to be identical to that by which Ags taken up by fluid phase pinocytosis traffick, suggesting that the accelerated BCR pathway may be specialized and potentially independently regulated.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10358163

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  23 in total

Review 1.  The cytoskeleton coordinates the early events of B-cell activation.

Authors:  Naomi E Harwood; Facundo D Batista
Journal:  Cold Spring Harb Perspect Biol       Date:  2011-02-01       Impact factor: 10.005

Review 2.  B cell superantigens: a microbe's answer to innate-like B cells and natural antibodies.

Authors:  Carl S Goodyear; Gregg J Silverman
Journal:  Springer Semin Immunopathol       Date:  2005-03

3.  Independent trafficking of Ig-alpha/Ig-beta and mu-heavy chain is facilitated by dissociation of the B cell antigen receptor complex.

Authors:  Jin-Hyang Kim; Lorraine Cramer; Heather Mueller; Bridget Wilson; Barbara J Vilen
Journal:  J Immunol       Date:  2005-07-01       Impact factor: 5.422

Review 4.  Effects of protein aggregates: an immunologic perspective.

Authors:  Amy S Rosenberg
Journal:  AAPS J       Date:  2006-08-04       Impact factor: 4.009

Review 5.  How B cells capture, process and present antigens: a crucial role for cell polarity.

Authors:  Maria-Isabel Yuseff; Paolo Pierobon; Anne Reversat; Ana-Maria Lennon-Duménil
Journal:  Nat Rev Immunol       Date:  2013-07       Impact factor: 53.106

6.  BCR ubiquitination controls BCR-mediated antigen processing and presentation.

Authors:  Lisa Drake; Erica M McGovern-Brindisi; James R Drake
Journal:  Blood       Date:  2006-08-24       Impact factor: 22.113

Review 7.  The use of signal peptide domains as vaccine candidates.

Authors:  Riva Kovjazin; Lior Carmon
Journal:  Hum Vaccin Immunother       Date:  2014-10-30       Impact factor: 3.452

8.  Actin-binding protein 1 regulates B cell receptor-mediated antigen processing and presentation in response to B cell receptor activation.

Authors:  Olusegun O Onabajo; Margaret K Seeley; Amruta Kale; Britta Qualmann; Michael Kessels; Jin Han; Tse-Hua Tan; Wenxia Song
Journal:  J Immunol       Date:  2008-05-15       Impact factor: 5.422

9.  The MHC class II cofactor HLA-DM interacts with Ig in B cells.

Authors:  Henriette Macmillan; Michael J Strohman; Sashi Ayyangar; Wei Jiang; Narendiran Rajasekaran; Armin Spura; Ann J Hessell; Anne-Marie Madec; Elizabeth D Mellins
Journal:  J Immunol       Date:  2014-08-06       Impact factor: 5.422

10.  Btk regulates B cell receptor-mediated antigen processing and presentation by controlling actin cytoskeleton dynamics in B cells.

Authors:  Shruti Sharma; Gregory Orlowski; Wenxia Song
Journal:  J Immunol       Date:  2009-01-01       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.